Japan Review Agency PMDA Subject To Streamlining Review
This article was originally published in PharmAsia News
Japan's Pharmaceutical and Medical Device Agency is among seven medical-related independent administrative entities that are subject to an organizational streamlining review by the government
You may also be interested in...
Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.
The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.